Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

Published byElinor Scott Modified over 8 years ago

Similar presentations

Presentation on theme: "1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory."— Presentation transcript:

1 1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory Committee & Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee Meeting February 2, 2004 Solomon Iyasu, MD, MPH Hari Cheryl Sachs, MD, FAAP Division of Pediatric Drug Development Center for Drug Evaluation and Research Food and Drug Administration

2 2 Best Pharmaceuticals for Children Act (BPCA) Jan 4, 2003 Section 17: Adverse Event (AE) Reporting –review all AEs for one year after granting pediatric exclusivity –report to the Pediatric Advisory Sub-Committee for review

3 3 Data Source for Drug Adverse Events FDA’s Adverse Event Reporting System (AERS) –spontaneous and voluntary reporting system –electronic database of postmarketing reports of adverse drug reactions –reporters include health care providers, pharmacies, consumers, and pharmaceutical manufacturers

4 4 Paroxetine Pediatric Psychiatric Adverse Events

5 5 Background Drug Information Moiety: Paxil ®, Paxil CR ® (paroxetine) Therapeutic Category: Antidepressant Sponsor: GlaxoSmithKline Adult Indications: Major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder –adult dose range: 20-60 mg/day There are NO approved pediatric indications Original market approval: December 1992 Pediatric exclusivity granted: June 27, 2002

6 6 Pregnancy Category C Precautions: –Suicide risk inherent in MDD –Suicide risk present in co-morbid conditions –Activation of mania –Seizures –Adverse events with abrupt discontinuation agitation, anxiety, dizziness, sensory disturbance, nausea and sweating Relevant Safety Labeling

7 7 Drug use trends: paroxetine Second most commonly used SSRI in children. 1 Both pediatric & adult prescriptions have increased steadily between 1999 and 2003. 1 Pediatric Diagnosis (off label): depression, anxiety and obsessive-compulsive disorders 2 Pediatric patients account for approximately 3.5 % of total U.S. prescriptions of Paxil ® between Jul 2002 – Jun 2003 (1.1 million). 1,3* 1 IMS Health, National Prescription Audit Plus , On-Line Source Year Aug 1999 – Jul 2003, Data Extracted Aug 2003 2 IMS Health, National Disease and Therapeutic Index , CD-Rom, Source 3 Year Jul 2000 – Jun 2003 3 AdvancePCS  Dimension Rx, On-Line *Calculation based on application of proportions of pediatric paroxetine prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of paroxetine prescriptions dispensed nationwide to pediatric population

8 8 Adverse Events 1992-2003: General Overview (raw counts) Total: over 17,000 adult and pediatric reports (68 % domestic) < 5 % of total are pediatric Top 20 pediatric AEs –similar to those reported in adults –majority labeled –unlabeled events related to maternal exposure Number of pediatric adverse event reports increased in 2002 compared with prior years

9 9 Raw Counts* of Pediatric Adverse Event Reports by Year (Dec 1992 to Jul 2003) * * includes duplicate reports

10 10 BBC show “The Secret of Seroxat,” aired October 13, 2002 British government warning issued on June 10, 2003 FDA Talk Paper issued on June 19, 2003 FDA PUBLIC ADVISORY for antidepressants and suicide issued on Oct 27, 2003 Exclusivity Period

11 11 Pediatric Adverse Events in the One-year Post -exclusivity Period Total unduplicated reports (N= 127) Gender: Female - 61, Male - 59, Unknown - 7 Age: 0-<2 yrs (n=32), 2-5 yrs (n=6), 6-11 yrs (n=33), 12-16 yrs (n= 55) & unknown (n=1) Outcomes: –10 % of reports were deaths (n = 13) –Approximately 1/3 hospitalizations/ER visit (n= 43)

12 12 Pediatric Adverse Events by Gender, Age & Exposure to Paroxetine (N=127) Gender: Female Male Unknown Age: 0-2 yrs 2-5yrs 6-11yrs 12-16yrs Unknown Maternal/Breastfeeding (n=33) 7 19 7 32 0 0 0 1 Direct Pediatric Exposure (n=94) 54 40 0 0 6 33 55 0

13 13 Pediatric Adverse Events: Reasons for Exposure to Paroxetine (N=127) Prenatal Exposure/Breastfeeding (n= 33) Direct Pediatric Exposure (n=94) –Depression/dysthymia - 28 –Anxiety/Panic/PTSD- 15 –ADHD- 2 –OCD- 1 –Multiple Psychiatric diagnosis- 18 –Other- 9 –Unknown - 21

14 14 Paroxetine: Pediatric Adverse Events Concomitant medications (n =55), exclusively paroxetine (n=5), most unknown (n= 67)Concomitant medications (n =55), exclusively paroxetine (n=5), most unknown (n= 67) Reporters: only 1/3 health professional; 2/3 consumer, media, litigation, etc.Reporters: only 1/3 health professional; 2/3 consumer, media, litigation, etc. Dose range 5-60 mg/day (n=65, excludes maternal/breastfeeding exposure)Dose range 5-60 mg/day (n=65, excludes maternal/breastfeeding exposure)

15 15 Pediatric Adverse Events: Predominant Events Psychiatric adverse events (68) Discontinuation Syndrome/decrease in dose (7) Maternal exposure (33) Neurologic events (8) Accidental ingestion (2) Other (9)

16 16 Psychiatric Adverse Events by Labeling Status (n=68 ) Labeled Completed suicide - 9 Suicidal attempts -17 Suicidal ideation - 11 Occurrence of other psychiatric symptoms - 9 Unlabeled Self-injurious behavior - 10 Completed homicide - 4 Aggression/Hostility/ Homicidal ideation - 8

17 17 Psychiatric Adverse Events (n=68) Demographics: –Gender: 57% Female –Age: 2-5 yrs. (5%), 6-11 yrs. (35%), 12-16 yrs. (60%) Concomitant medications described in only 24 patients – 20 of the 24 on other psychotherapeutic agent discontinuation or decrease in dose noted in 11 of the 68 patients with psychiatric events

18 18 Psychiatric Events with Discontinuation or Decrease in Dose Completed suicide (1 out of 9 ) Suicidal attempts (5 out of 17) Homicide (2 out of 4) Aggression/Hostility/Homicidal ideation (3 out of 8)

19 19 Suicide Attempts (n=17) Diagnosis: Majority MDD, Bipolar Disorder Concomitant medications in approximately one third discontinuation or decrease in dose in approximately one fourth

20 20 Pediatric Deaths (n=13) 10 deaths involving direct pediatric exposures –9 completed suicides –1 case of Stevens Johnson Syndrome; patient also received valproic acid 3 deaths among patients with prenatal exposure

21 21 Pediatric Deaths: Completed Suicides (n=9) –Ages 12-16 years –Gender Female (5) Male (4) –Initial Diagnosis: MDD (5) Explosive Disorder (1) Unknown (3) –Duration of treatment- 14 days to 1 year –Discontinuation or decrease in dose (2) –Concomitant medication (4) –Possible substance abuse (4) –History of prior attempts (3)

22 22 Factors Contributing to Difficulty in Assessing Causality Patient Factors –severity of illness/ underlying disease –prior history of suicide attempts –concomitant medication –substance abuse Reporting factors –inadequate detail in describing event –timing of event in relationship to medication –ascertainment of reported events –lack of follow-up

23 23 Limitations of AERS Spontaneous and voluntary system –Underreporting –Reporting bias (media publicity, length of time in market) –Report quality may vary (missing details e.g. concomitant medications) –Cannot estimate true incidence rate of events or exposure risk

24 24 Closing Observations The psychiatric events described in the adverse event reports may reflect: –underlying disease –drug adverse effect –lack of drug effect Evaluation of controlled trials necessary to sort out

25 25 Acknowledgements ODS reviews prepared by: Mark Avigan, MD, C. M. Susan Lu, R. Ph Carol Pamer, R. Ph Toni Piazza-Hepp, Pharm.D. Gianna Rigoni, Pharm.D.

26 26 Citalopram: Pediatric Psychiatric Adverse Events Solomon Iyasu, MD, MPH Hari Cheryl Sachs, MD, FAAP Division of Pediatric Drug Development

27 27 Citalopram: Background Drug Information Moiety: Celexa ® (citalopram) Therapeutic Category: Antidepressant Sponsor: Forest Pharmaceuticals Adult Indication: Major Depressive Disorder –Adult dose range: 20-40 mg/day There are NO approved pediatric indications Original market approval: July 17, 1998 Pediatric exclusivity granted: July 9, 2002

28 28 Relevant Safety Labeling Pregnancy Category C Excreted in human breast milk Precautions: –Suicide risk inherent in depression –Activation of mania/hypomania –Any psychoactive agent may impair intellectual or psychomotor functions –Seizures: introduce citalopram with care

29 29 Relevant Safety Labeling (cont.) Adverse Reactions –Agitation –Pre marketing reports Frequent: impaired concentration, depression, suicide attempt, confusion Infrequent: aggressive reaction, psychotic reaction, delusion, paranoid reaction, emotional lability, panic reaction

30 30 Drug use trends: Citalopram 4th most commonly used SSRI in children 1 Both pediatric and adult prescriptions have increased between 1999 and 2003 1 Pediatric patients account for approximately 3.3% (665, 000) of the total U.S. prescriptions of Celexa ® during Jul 2002- Jul 2003 1,2 Pediatric Diagnosis (off label): depressive disorders, obsessive-compulsive disorder and attention deficit disorder 3 1 IMS Health, National Prescription Audit Plus , On-Line Source Year Aug 1999 – Jul 2003, Data Extracted Aug 2003 2 AdvancePCS  Dimension Rx, On-Line, Jul 2001 – Jun 2003 3 IMS Health, National Disease and Therapeutic Index , CD-Rom, Source 3 Year Jul 2000 – Jun 2003 *Calculation based on application of proportions of pediatric citalopram prescriptions in AdvancePCS  to IMS Health, National Prescription Audit Plus  to estimate number of citalopram prescriptions dispensed nationwide to pediatric population

31 31 Overview of Adverse Event Reports Since Marketing Approval Total: over 6,000 reports (79% domestic) <5 % of total are pediatric Top 20 AE –All adverse events related to in utero exposure were unlabeled –Adverse event reports for children involving direct exposure were generally similar to those reported for adults

32 32 Pediatric Adverse Events in the One-Year Post-exclusivity Period Total unduplicated reports (n=42) 16 in utero exposures; resulted in unlabeled events and one death 26 children involving direct exposure, 8 unlabeled events, no deaths –16 serious AEs (10 hospitalization, 4 life- threatening, 2 with disability) –dose 5-60 mg/day, median dose 20 mg/day

33 33 Pediatric Adverse Events by Gender, Age and Exposure GENDER In Utero Exposure (n=16) Direct Exposure (n=26) Female1117 Male29 Unknown30 AGE 0-2 yrs151 2-5 yrs11 6-11 yrs09 12-16 yrs015

34 34 Pediatric Adverse Events: Reasons for Exposure to Citalopram In utero exposures – 16 Direct Pediatric Exposure – 26 –Depression – 13 –Ingestion of another person’s prescription – 2 –Other – 5 –Unknown - 6

35 35 Citalopram adverse events- Psychiatric (n= 5) Labeled Cognitive impairment Aggression Agitation, mania, and delusions Suicidality Psychotic reaction Unlabeled Violent/homicidal behavior

36 36 Citalopram Adverse Events- Psychiatric (cont.) Gender: 4 males, 1 female Age: 6-11 yrs (2), 11-16 yrs (3) Diagnosis: MDD (4), ODD(1) Concomitant medications – 2 – Prozac®; Keppra®, clonazepam Symptoms resolved when citalopram discontinued - 4

37 37 Closing observations Few psychiatric events were reported Unable to determine causality due to limitations of AERS FDA will continue monitoring these adverse events in children

38 38 Acknowledgements ODS reviews prepared by: Mark Avigan, MD Toni Piazza-Hepp, Pharm.D. Kathleen Phelan, R. Ph Gianna Rigoni, Pharm.D.

Download ppt "1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory."

Similar presentations

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.

Antiepileptic Drugs and Suicidality: Background Evelyn Mentari, M.D., M.S. Clinical Safety Reviewer Division of Neurology Products/CDER Food and Drug Administration.
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, 2004 1 Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.
Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.

Suicidality and Anti-epileptic Drugs: Status of Clinical Trial Data Analysis Evelyn Mentari, MD, MS Division of Neurology Products.
Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.

Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.
1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.

1 One Year Post Exclusivity Adverse Event Review: Fentanyl Transdermal System Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,

1 One Year Post Exclusivity Adverse Event Review: Atovaquone-Proguanil Pediatric Advisory Committee Meeting February 14, 2005 Alan M. Shapiro, MD, PhD,
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.

Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.
1 Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide Mary Ross Southworth, PharmD Safety Evaluator,

1 Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide Mary Ross Southworth, PharmD Safety Evaluator,
Mental Health and the Athlete

Mental Health and the Athlete
Meredith Bailey, LCSW Timberlawn Hospital February 26, 2009 1.

Meredith Bailey, LCSW Timberlawn Hospital February 26,
Continuity Clinic Depression. Continuity Clinic Objectives.

Continuity Clinic Depression. Continuity Clinic Objectives.
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.
1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.

1 One Year Post Exclusivity Adverse Event Review: Alendronate Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP Medical.
Background Development of Anxiety Among Depressed Veterans After Antidepressant Usage Zhiguo Li, Paul Pfeiffer, Katherine Hoggatt, Kara Zivin, Karen Downing.

Background Development of Anxiety Among Depressed Veterans After Antidepressant Usage Zhiguo Li, Paul Pfeiffer, Katherine Hoggatt, Kara Zivin, Karen Downing.
Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.

Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
1 One Year Post-Pediatric Exclusivity Postmarketing Adverse Event Review SERTRALINE ( Zoloft) Dr. Solomon Iyasu Medical Team Leader Division of Pediatric.

1 One Year Post-Pediatric Exclusivity Postmarketing Adverse Event Review SERTRALINE ( Zoloft) Dr. Solomon Iyasu Medical Team Leader Division of Pediatric.

Similar presentations

Ads by Google